3 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 77 points (0.5%) at 16,913 as of Friday, June 6, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,319 issues advancing vs. 667 declining with 134 unchanged.

The Drugs industry currently sits up 1.5% versus the S&P 500, which is up 0.4%. Top gainers within the industry include Grifols ( GRFS), up 3.1%, and Shire ( SHPG), up 0.8%. On the negative front, top decliners within the industry include Biomarin Pharmaceutical ( BMRN), down 2.8%, Biogen Idec ( BIIB), down 1.2%, Gilead ( GILD), down 0.8% and Valeant Pharmaceuticals International ( VRX), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Illumina ( ILMN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Illumina is up $2.84 (1.7%) to $166.93 on heavy volume. Thus far, 1.9 million shares of Illumina exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $163.11-$167.40 after having opened the day at $166.45 as compared to the previous trading day's close of $164.09.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $20.7 billion and is part of the health care sector. Shares are up 48.4% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AstraZeneca ( AZN) is up $0.65 (0.9%) to $72.89 on light volume. Thus far, 1.7 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $72.07-$73.00 after having opened the day at $72.11 as compared to the previous trading day's close of $72.24.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $91.6 billion and is part of the health care sector. Shares are up 22.4% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates AstraZeneca a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Actavis ( ACT) is up $1.49 (0.7%) to $209.49 on light volume. Thus far, 823,405 shares of Actavis exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $207.50-$210.18 after having opened the day at $208.19 as compared to the previous trading day's close of $208.00.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $36.8 billion and is part of the health care sector. Shares are up 25.6% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk. Get the full Actavis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing